Polymorphisms of norepinephrine transporter and adrenergic receptor α1D are associated with the response to β-blockers in dilated cardiomyopathy
暂无分享,去创建一个
S. Nonen | Y. Fujio | J. Azuma | A. Kitabatake | H. Okamoto | M. Yoshiyama | J. Yoshikawa | Y. Matsui | Y. Takemoto | T. Hamaguchi
[1] Julie A. Johnson,et al. Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. , 2005, Pharmacogenetics and genomics.
[2] H. Nakano,et al. Usefulness of meta-[123I]iodobenzylguanidine myocardial scintigraphy for predicting cardiac events in patients with dilated cardiomyopathy who receive long-term beta blocker treatment , 2005, Nuclear medicine communications.
[3] M. Iyo,et al. Haplotype association between GABAA receptor γ2 subunit gene (GABRG2) and methamphetamine use disorder , 2005, The Pharmacogenomics Journal.
[4] H. Kroemer,et al. CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects , 2004, Clinical pharmacology and therapeutics.
[5] S. Hosoda,et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. , 2004, American heart journal.
[6] S. Coca,et al. COMET: a proposed mechanism of action to explain the results and concerns about dose , 2003, The Lancet.
[7] G. Dorn,et al. β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure , 2003, Nature Medicine.
[8] P. Poole‐Wilson,et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.
[9] G. Jennings,et al. Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. , 2003, Pharmacogenetics.
[10] G. Tsujimoto,et al. Differential Cardiovascular Regulatory Activities of the α1B- and α1D-Adrenoceptor Subtypes , 2003, Journal of Pharmacology and Experimental Therapeutics.
[11] G. Tsujimoto,et al. Differential cardiovascular regulatory activities of the alpha 1B- and alpha 1D-adrenoceptor subtypes. , 2003, The Journal of pharmacology and experimental therapeutics.
[12] G. Tsujimoto,et al. Role of the α1D-Adrenegric Receptor in the Development of Salt-Induced Hypertension , 2002 .
[13] G. Eisenhofer. The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. , 2001, Pharmacology & therapeutics.
[14] S. Liggett,et al. A Four Amino Acid Deletion Polymorphism in the Third Intracellular Loop of the Human α2C-Adrenergic Receptor Confers Impaired Coupling to Multiple Effectors* , 2000, The Journal of Biological Chemistry.
[15] M. Laakso,et al. Identification of a three-amino acid deletion in the alpha2B-adrenergic receptor that is associated with reduced basal metabolic rate in obese subjects. , 1999, The Journal of clinical endocrinology and metabolism.
[16] Fach,et al. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.
[17] M. Lai,et al. Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes , 1999, Clinical pharmacology and therapeutics.
[18] F. Follath,et al. Etiology and response to drug treatment in heart failure. , 1998, Journal of the American College of Cardiology.
[19] Britton,et al. β2‐adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in an adult population , 1998, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[20] C. Visser,et al. Ejection fraction improvement by beta-blocker treatment in patients with heart failure: an analysis of studies published in the literature. , 1998, Journal of cardiovascular pharmacology.
[21] I. Narabayashi,et al. Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to beta-blocker therapy in patients with dilated cardiomyopathy. , 1997, American heart journal.
[22] J. Cohn,et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.
[23] G. Tucker,et al. Oxidation phenotype--a major determinant of metoprolol metabolism and response. , 1982, The New England journal of medicine.